Nachrichten zur Myriad Genetics Inc. Aktie

^Next-Generation-Sequencing-Test für homologe Rekombinationsdefizienz (HRD)basierend auf QIAGENs QIAseq-xHYB-Technologie, QIAGEN Digital Insight Lösungenund…

Next-Generation-Sequencing-Test für homologe Rekombinationsdefizienz (HRD) basierend auf QIAGENs QIAseq-xHYB-Technologie, QIAGEN Digital Insight Lösungen und proprietären, von der FDA zugelassenen ...…

…

Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in…

The Global Theranostics Market Size was Valued at USD 1.9 Billion in 2023 and the Worldwide Theranostics Market Size is…

Myriad Genetics (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.…

Investors are optimistic about Myriad Genetics (MYGN) strong solvency position and improvement in testing volume.…

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Myriad Genetics (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to…

Salt Lake City, Utah, March 13, 2024 (GLOBE NEWSWIRE) -- BioHive, a nonprofit public-private partnership dedicated to enhancing…

Myriad Genetics (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential…

Myriad Genetics target raised to $28 on firm outlook…

Earnings call: Myriad Genetics reports positive 2023 results, eyes growth…

…

Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.…

…

Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types Myriad’s…